Ecuador Medical Device Risk Classification I-IV: Rules and Practical Guidance

1. Key takeaways

Ecuador uses four risk classes: Class I (low risk), Class II (moderate-low risk), Class III (moderate-high risk) and Class IV (high risk). Classification is carried out under the instructivo issued by ARCSA, and the rules derive from GHTF, whose work is now carried by IMDRF. Article 22 establishes 5 determination rules, the core being that devices used in combination are classified separately and the highest class is taken; standalone commercialized SaMD is classified under the IMDRF/N12 matrix.

2. Legal basis

Official class names in Article 21: 1. Nivel de Riesgo I (Riesgo Bajo); 2. Nivel de Riesgo II (Riesgo Moderado Bajo); 3. Nivel de Riesgo III (Riesgo Moderado Alto); 4. Nivel de Riesgo IV (Riesgo Alto).

3. Expert insights

Insight one: the official names of the four classes are low, moderate-low, moderate-high and high, not low, medium, high and very high. Chinese-language materials often render Class IV as very high risk, but the original text is Riesgo Alto (high risk), while Class III is Moderado Alto (moderate-high risk). This difference produces inconsistent classification statements in tenders and technical document translations, so the official names should be used uniformly.

Insight two: the classification basis is a dynamic document, the ARCSA instructivo, not a fixed regulation. Article 22 states at the outset that ARCSA will apply the corresponding instructivo. General provision TERCERA further confirms that classification follows the guidelines and rules developed by GHTF and now carried by IMDRF, and that ARCSA may update the classification rules in light of technical progress and the recommendations of international organizations. Classification rules are therefore a living document and the instructivo version must be tracked.

Insight three: the 5 rules of Article 22 cover the four situations most disputed in practice.

• (a) Determination baseline: the risk class is set by the potential harm to the patient, considering four factors, the intended purpose, the degree of intervention in the body, the technology employed and the duration of residence in the body;
• (b) Accessories: accessories of a device may be classified separately, following the classification rules of the corresponding instructivo;
• (c) Combination use: where a device is intended to be used in combination with other devices, the rules apply separately to each device and the highest risk class is taken;
• (d) Embedded software: software used in combination with another device automatically takes the same risk class as the device to which it applies, and is accordingly covered by the same registration certificate;
• (e) Standalone software: SaMD commercialized on its own is classified under the IMDRF/N12 risk matrix.

Insight four: the difference between (c) and (d) is take-the-highest versus follow-the-host, and these two rules are frequently confused. Under (c), two independent devices are each classified and the higher class is taken; under (d), software simply follows the class of the host device without separate classification. This distinction determines whether a separate classification argument must be submitted for the software.

Insight five: combination devices incorporating pharmaceutical substances are handled separately in Article 24. Combination devices must state the generic name (DCI) of the active ingredient and its qualitative and quantitative formulation, and this is required only for Classes II, III and IV of DMI and DMNI devices.

4. Practical recommendations

1. Build a written file for every classification conclusion, stating the applicable ARCSA instructivo version and the reasoning.
2. For combination products, classify each component first and then set the overall class under the take-the-highest principle, avoiding rejections of the combined submission.
3. Software sold with hardware should be placed directly in the class of the host device and its certificate, without a separate classification argument.
4. Self-assess standalone commercialized SaMD against the IMDRF/N12 matrix and retain the matrix determination for the record.
5. For borderline products between Class IV and Class I, obtain written pre-confirmation from ARCSA through the local representative before submission, avoiding rework caused by preparing the dossier under the wrong class.

5. Verification checklist

• □ Risk classes have been labeled with the official names (low, moderate-low, moderate-high, high)
• □ The applicable ARCSA classification instructivo has been confirmed as the latest version
• □ Combination products have been classified component by component, taking the highest class
• □ Software sold with hardware has been placed in the class and registration certificate of the host device
• □ Standalone commercialized SaMD has completed the IMDRF/N12 matrix self-assessment
• □ Combination devices have prepared the DCI and the qualitative and quantitative formulation, where applicable

Regulatory information verified as of October 29, 2026

GRZAN core service lines

1. Global registration access: EU CE (MDR/IVDR), US FDA (510(k)/De Novo/PMA), UK UKCA, Australia TGA, Canada Health Canada, Brazil ANVISA and Russia RZN, together with pre-market registration pathway planning and submission execution across Latin America, Southeast Asia and the Middle East.
2. Authorized representative services: EU EC REP, UK RP, Swiss CH REP, Australian sponsor and US Agent holding and representation services, with support for neutral license-holder structures.
3. Quality system compliance: ISO 13485 establishment and maintenance, MDSAP audit preparation, GMP conformity coaching, and technical documentation (TD) drafting and remediation.
4. Clinical and evaluation support: clinical evaluation plans (CEP) and reports (CER), equivalence argumentation, PMCF planning and execution, and IVD performance evaluation.
5. Post-market compliance: vigilance and adverse event reporting, FSCA and recall execution, registration change and renewal management, and maintenance of national regulatory databases.

Why manufacturers choose GRZAN

• Local regulatory teams: target-market work is performed by locally licensed regulatory professionals, and submission dossiers are written directly in the local official language without secondary translation.
• Neutral license-holder structures: GRZAN offers holding arrangements that are not tied to any distribution channel, preventing registration certificates from being locked in by channel partners.
• Regional leverage: one technical dossier can be reused across Andean Community and Mercosur member states, spreading regional compliance costs.
• Full lifecycle support: from classification determination and pathway design through dossier preparation, license holding, customs clearance, post-market vigilance and renewal.

Contact

• GRZAN provides registration support in Ecuador for manufacturers, importers and authorized representatives.
• Email: info@grzanglobal.com
• Service inquiries: Ecuador and Andean market registration plans, license-holder structure design, official fee and timeline estimation